Results 171 to 180 of about 753,352 (304)

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma‐cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study

Molecular Oncology, EarlyView.
Circulating tumor cells (CTCs) and plasma cell‐free DNA (cfDNA) were analyzed to detect ESR1 mutations and methylation in patients with advanced breast cancer. CTC‐derived DNA showed higher sensitivity for mutation detection and revealed complementary genetic and epigenetic alterations, highlighting the added value of CTC analysis for understanding ...
Dimitra Stergiopoulou, Athina Markou, Eleonora Nicolo, Mara S Serafini, Qiang Zhang, Youbin Zhang, Lorenzo Gerratana, Andrew A. Davis, Huiping Liu, William J Gradishar, Carolina Reduzzi, Massimo Cristofanilli, Evi Lianidou   +12 more
wiley   +1 more source

GENETICS AND HEALTH: POLICY ISSUES FOR GENETIC SCIENCE AND THEIR IMPLICATIONS FOR HEALTH AND HEALTH SERVICES

, 2000
Acknowledgements -- Foreword -- I. Introduction -- II. The process -- III. The policy context -- Introduction -- National context -- Service provision -- Insurance -- Statutory provision and legislation in the United Kingdom -- International ...
Cook, Christopher, Nuffield Trust for Research and Policy Studies in Health Services; Nuffield Trust Genetics Scenario Project; and Public Health Genetics Unit, Zimmern, Ron   +2 more
core  

Interdisciplinary vascular genetics evaluations in routine clinical care: insights from a five-year single-center experience. [PDF]

Langenbecks Arch Surg
Burkart S, Sailer S, Körfer D, Marbach F, Spanjaard M, Hirsch S, Brennenstuhl H, Valentin I, Hinderhofer K, Dennig J, Kaufmann L, Schaaf CP, Böckler D, Dikow N, Hempel M, Erhart P.   +15 more
europepmc   +1 more source

Interpreting the effects of DNA polymerase variants at the structural level

Molecular Oncology, EarlyView.
Using MAVISp and molecular dynamics simulations, we analyzed over 60 000 missense variants in POLE and POLD1 from ClinVar, COSMIC, cBioPortal, and saturation mutagenesis. Identified mechanistic indicators, including stability, binding, and long‐range, enable structural interpretation, providing ACMG‐like evidence for possible reclassification of VUS ...
Matteo Arnaudi, Karolina Krzesińska, Ludovica Beltrame, Pablo Sánchez‐Izquierdo Besora, Matteo Tiberti, Mef Nilbert, Anna Rohlin, Elena Papaleo   +7 more
wiley   +1 more source

Correction: Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017. [PDF]

Breast Cancer
Tanaka K, Shimomura A, Ishitobi M, Yamanaka T, Tsukioki T, Iwata H, Hara F, Fujisawa T, Sasaki K, Sadachi R, Kajikawa R, Sakai T, Sagara Y, Shigematsu H, Ozaki Y, Nozawa K, Sudo K, Naito Y, Terata K, Ishiba T, Fukuda H, Shien T.   +21 more
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Publisher Correction: Multi-ancestry genome-wide association analyses of refractive error augment genetic discovery and polygenic prediction. [PDF]

Nat Genet
Cheng FF, Liu X, Mi H, Wang L, Ma R, Guo Y, Sidorenko J, Jiang C, Islam T, Meguro A, Hikino K, Ishikawa Y, Tang S, Li T, Chen R, Wang L, Mägi R, Metspalu A, Estonian Biobank Research Team, 23andMe Research Team, Takeuchi M, Mizuki N, Choquet H, Jin ZB, Chen G, Zhou K, Terao C, Zeng J, Yang J.   +28 more
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Development and validation of a rule-based tool for quality management reporting in a genetics laboratory. [PDF]

Pract Lab Med
Trad F, Doghman J, Sayegh S, Chehab A, Assaf N.   +4 more
europepmc   +1 more source

DNA methylation and expression of MAPRE3 affect overall survival of early‐stage non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
Both cg12821679MAPRE3 methylation and MAPRE3 expression are significantly associated with overall survival (OS) of non‐small cell lung cancer. Meanwhile, MAPRE3 expression significantly modified the effect of smoking cessation on OS. Smoking cessation benefits OS merely for patients with high MAPRE3 expression.
Chao Chen, Jiancheng Cheng, Ruili Hou, Xiaoyuan Zheng, Li Su, Maria Moksnes Bjaanæs, Anna Karlsson, Maria Planck, Johan Staaf, Åslaug Helland, Manel Esteller, David C. Christiani, Feng Chen, Xiaofei Cao, Ruyang Zhang   +14 more
wiley   +1 more source